295 related articles for article (PubMed ID: 25521760)
1. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
2. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences.
Montico F; Kido LA; San Martin R; Rowley DR; Cagnon VH
Prostate; 2015 Oct; 75(14):1643-61. PubMed ID: 26184673
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and prostate cancer: identification of a molecular progression switch.
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and finasteride therapies: responses of the prostate microenvironment in elderly mice.
Kido LA; Hetzl AC; Cândido EM; Montico F; Lorencini RM; Cagnon VH
Life Sci; 2014 Jun; 106(1-2):58-70. PubMed ID: 24792519
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
6. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Huss WJ; Barrios RJ; Greenberg NM
Mol Cancer Ther; 2003 Jul; 2(7):611-6. PubMed ID: 12883033
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.
Montico F; Kido LA; Hetzl AC; Lorencini RM; Cândido EM; Cagnon VH
Histochem Cell Biol; 2014 Sep; 142(3):269-84. PubMed ID: 24562790
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract][Full Text] [Related]
9. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.
Macpherson GR; Ng SS; Forbes SL; Melillo G; Karpova T; McNally J; Conrads TP; Veenstra TD; Martinez A; Cuttitta F; Price DK; Figg WD
Mol Cancer Ther; 2003 Sep; 2(9):845-54. PubMed ID: 14555703
[TBL] [Abstract][Full Text] [Related]
11. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S
Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
Krishnan B; Torti FM; Gallagher PE; Tallant EA
Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
15. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.
Gabril M; Xuan J; Moussa M; Dinney CP; Chin JL; Izawa JI
Urology; 2004 Dec; 64(6):1233-7. PubMed ID: 15596214
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth.
Yang KQ; Liu Y; Huang QH; Mo N; Zhang QY; Meng QG; Cheng JW
BMC Cancer; 2017 Dec; 17(1):878. PubMed ID: 29268703
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.
Zhang K; Wang Y; Yu X; Shi Y; Yao Y; Wei X; Ma X
BMC Cancer; 2017 Dec; 17(1):899. PubMed ID: 29282026
[TBL] [Abstract][Full Text] [Related]
19. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
